Supplementary Figure S3. IDFS by HER2 IHC score at definitive surgery (derived from samples used for eligibility and exploratory purposes). IDFS, invasive disease-free survival; IHC, immunohistochemistry; T-DM1, trastuzumab emtansine.

Baseline Risk Factors	Total n	Trastuzumab (n = 743)			T-DM1 (n = 743)					
		Patients Per Group	Events	3-Year IDFS	Patients Per Group	Events	3-Year IDFS	Hazard Ratio	95% CI	T-DM1 Trastuzumab Better Better
All	1486	743	165	77.0	743	91	88.3	0.50	(0.39–0.64)	- - -
Central HER2 IHC status at surgery										i i i i i i i i i i i i i i i i i i i
0/1+	70	48	11	76.9	22	3	89.5	0.66	(0.18-2.38)	< <u>↓</u>
2+	351	176	33	80.7	175	24	87.6	0.68	(0.40-1.16)	┍┶╌╋┥
3+	753	360	94	72.4	393	39	90.2	0.33	(0.23-0.48)	⊢–∎––4¦
									0	.20 0.50 1 2